表浅膀胱癌术后膀胱灌注吡柔比星与丝裂霉素的疗效对比  

Comparison of therapeutic efficacy of pirarubicin and mitomycin by intravesical instillation after superficial bladder cancer surgery

作　　者：钟锦卫 

机构地区：[1]广州市番禺区中心医院泌尿外科,广东广州511400

出　　处：《西部医学》2013年第2期220-221,224,共3页Medical Journal of West China

摘　　要：目的对比分析表浅膀胱癌术后膀胱灌注吡柔比星与丝裂霉素的疗效与安全性。方法 152例表浅膀胱癌患者予经尿道膀胱肿瘤电切术(TURBT)或膀胱部分切除术治疗,然后再将他们随机分为观察组(n=76)与对照组(n=76),前者接受膀胱灌注吡柔比星治疗,后者接受膀胱灌注丝裂霉素治疗。在治疗结束后对所有患者进行随访,随访期为3年。结果观察组术后复发率显著低于对照组,两组比较差异有统计学意义(χ2=3.8778,P=0.0492);观察组不良反应发生率显著高于对照组,两组比较差异有统计学意义(χ2=11.1930,P=0.0000)。结论膀胱灌注吡柔比星与丝裂霉素治疗表浅膀胱癌患者各有其特点,前者的疗效较好,后者的耐受性较好。Objective To compare the therapeutic efficacy and safety of pirarubicin and mitomycin by intravesical instillation after superficial bladder cancer surgery. Methods 152 cases of superficial bladder cancer who were admitted into our hospital from January 2006 to February 2009 were given transurethral bladder tumor resection （TURBT） or partial cystectomy, and then this patients were divided into the observation group （n= 76） and the control group（n= 76） randomly, and the former received intravesical instillation of pirarubicin, while the latter was given mitomycin. All patients were followed up for 3 years after treatment. Results The recurrence rate of the observation group was significantly lower than that of the control group（χ2 =3. 8778 ,P=0. 0492）. QThe incidence rate of adverse reactions of the observation group was significantly higher than that of the control group（χ2 =11. 1930,P=0. 0000）. Conclusion The intravesical instillation Of pirarubicin and mitomycin in the treatment of superficial bladder cancer have their own characteristics, and the former has better efficacy, but the latter is better tolerated.

关 键 词：表浅膀胱癌 膀胱灌注 吡柔比星 丝裂霉素 

分 类 号：R737.14[医药卫生—肿瘤]